Experts from Lurie Cancer Center and Northwestern Medicine Present at 2019 ASCO Annual Meeting

Physicians and scientists from the Robert H. Lurie Comprehensive Cancer Center of Northwestern University and Northwestern Medicine will present the latest clinical research impacting cancer care at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting.

Held from Friday, May 31, through Tuesday, June 4 at McCormick Place in Chicago, the theme for the 2019 ASCO Annual Meeting is “Caring for Every Patient, Learning from Every Patient.”

Visit Lurie Cancer Center and Northwestern Medicine in the exhibit hall at Booth 2015.

Use #ASCO19 to Follow and Share on Twitter                                                                                                  

Lurie Cancer Center: @LurieCancer
Northwestern Medicine: @NorthwesternMed
Feinberg School of Medicine: @NUFeinbergMed

 

Lead authors who will be presenting research, and Lurie Cancer Center members who will be leading sessions at the meeting include:

 

Friday, May 31

Jessica K. Altman, MD

2:45 p.m.

Molecular Analysis of Myeloid Disorders: Is Precision Medicine Changing Practice (Chair)

3:25 p.m.

Targeting Treatment According to Molecular Assessment of Acute Myeloid Leukemia

 

Saturday, June 1

Alicia K. Morgans, MD

8:00 a.m.

Fireside Chat: Including the Patient Experience in Oncology Clinical Trial Design and the Regulatory Process (Moderator)

Priya Kumthekar, MD

8:00 a.m.

A phase 0 first-in-human study using NU-0129: A gold base spherical nucleic acid (SNA) nanoconjugate targeting BCL2L12 in recurrent glioblastoma patients

Lorenzo Gerratana, MD

8:00 a.m.

Can the enumeration of circulating tumor cells (CTCs) and the characterization of circulating tumor DNA (ctDNA) provide insight into organ tropism in metastatic breast cancer (MBC)?

Andrew A. Davis, MD

8:00 a.m.

Whole-genome cell-free DNA (cfDNA) changes as a dynamic blood-based biomarker for early response assessment of advanced tumors.

&

A prospective study tracking longitudinal changes in genome-wide cell-free DNA (cfDNA) methylation to identify early nonresponders to cancer treatment

Maha Hussain, MD, FACP, FASCO

8:15 a.m.

Fireside Chat: Including the Patient Experience in Oncology Clinical Trial Design and the Regulatory Process (Regulatory Perspective)

Navdeep Chandel, PhD

1:15 p.m.

Discovering Therapeutic Metabolic Targets in Solid Tumors

Wendy Swetzig, PhD

1:15 p.m.

Efficacy and safety of tivozanib in recurrent, platinum-resistant ovarian, fallopian tube or primary peritoneal cancer

Judith Paice, PhD, RN

1:45 pm

Safe and Effective Opioid Prescribing for Patients Receiving Cancer-Directed Therapy

 

Sunday, June 2

Edward M. Schaeffer, MD, PhD

8:00 a.m.

Defining Oligometastatic Disease: Shifting Definitions and Potential Effects on Patient Outcomes

Priya Kumthekar, MD

8:00 a.m.

A phase II trial of bevacizumab in patients with recurrent solid tumor brain metastases who have failed whole brain radiation therapy (WBRT) 

Ami Shah, MD

8:00 a.m.

A phase II study of pembrolizumab and capecitabine for triple-negative (TN) and hormone receptor-positive, HER2-negative endocrine-refractory metastatic breast cancer (MBC)

Daniela Matei, MD

8:00 a.m.

Clinical Science Symposium: Gynecologic Cancer (Chair)

Are We Hitting the Bull’s Eye with Targeted Therapy

Qiang Zhang, MD, PhD

8:00 a.m.

Association of Her2 alterations and ESR1 mutations in cell-free DNA (cfDNA) with circulating tumor cells (CTCs), multiple metastasis, and prognosis in stage III/IV breast cancer (BCa)

Rimas Lukas, MD 

8:00 a.m.

Evaluation of Controlled IL-12 as monotherapy in subjects with recurrent GBM

Christine Weldon, MBA

8:00 a.m.

Does the innovative 4R Care Delivery Model improve timing and sequencing of guideline recommended breast cancer care in safety net and non-safety net centers?

Vinai Gondi, MD

8:00 a.m.

A randomized phase II/III trial of prophylactic cranial irradiation with or without hippocampal avoidance for small cell lung cancer

4:30 p.m.

NRG Oncology CC001: A phase III trial of hippocampal avoidance (HA) in addition to whole-brain radiotherapy (WBRT) plus memantine to preserve neurocognitive function (NCF) in patients with brain metastases (BM)

Victoria M. Villaflor, MD

4:45 p.m.

Liquid Biopsy: How to Interpret and Use Results in Clinical Practice

Stewart Goldman, MD

4:45 p.m.

Point/Counterpoint: Proton Versus Photon in Radiation Therapy (Chair)
Neuro-Oncology Perspectives on Radiotherapy

 

Monday, June 3

Barbara Pro, MD

8:00 a.m.

Time to next treatment in patients with previously treated cutaneous T-cell lymphoma (CTCL) receiving mogamulizumab or vorinostat: A MAVORIC post-hoc analysis

Reem Karmali, MD

8:00 a.m.

Ibrutinib maintenance following induction for untreated mantle cell lymphoma (MCL): Initial safety report

Riad Salem, MD

8:20 a.m.

Meet the Professors: Surgery, Liver-Directed Treatment, or Systematic Therapy—Where Are the Boundaries for Hepatic Metastases?

Alicia Morgans, MD   

1:15 p.m.  

Treatment (tx) characteristics of patients (pts) with locally advanced or metastatic urothelial cancer (mUC) receiving checkpoint inhibitor (CPI) monotherapy in a US clinical practice

Katrina Alber, MPH

1:15 p.m.

Phase I trial of endoxifen gel versus placebo gel in women undergoing breast surgery

Sunandana Chandra, MD

4:30 p.m.

Melanoma/Skin Cancers (Chair)